Objective We describe cases of invasive group A Streptococcus (iGAS) in mothers or neonates and assess management according to national guidelines, which recommend administering antibiotics to both mother and neonate if either develops iGAS infection within 28 days of birth and investigation of clusters in maternity units.
Introduction
Streptococcus pyogenes, or group A Streptococcus (GAS), is a bacterium associated with a number of diseases, from mild presentations such as pharyngotonsillitis and impetigo to life-threatening invasive GAS infection (iGAS). Along with group B Streptococcus, Escherichia coli (E. coli), Staphylococcus aureus (S. aureus) and Streptococcus pneumoniae (S. pneumoniae), GAS is among the most common organisms causing puerperal sepsis. 1 Defined as systemic infection developing around the time of childbirth until 6 weeks postpartum, puerperal sepsis can result in maternal death, 2 with around ten sepsis-related maternal deaths occurring per year in the UK. 3 For each maternal sepsis death, an estimated 50 women have life-threatening morbidity from sepsis. 4 The risk of secondary iGAS infection in close contacts of cases is elevated, particularly for mothers and their infants during the neonatal period, with an attack rate of over 25 per 100 person-years at risk, 5 although the risk of death is not elevated compared with other iGAS infections. As GAS is not usually carried in the vaginal flora, genital exposure peripartum arising from an exogenous source may be the cause of the high risk of iGAS infection.
Guidelines for the management of close community contacts of iGAS infection issued in 2004 state that antibiotic prophylaxis should be administered to both mother and neonate if either develops suspected or confirmed iGAS infection during the neonatal period (the first 28 days following birth). 6 A review of linked maternal/neonate cases found that to avert one case, 50 contacts need to receive prophylaxis. 5 In England and Wales, iGAS infection was made a notifiable disease in 2010. 7, 8 All cases should be rapidly reported to local Public Health England (PHE) health protection teams (HPTs) so that immediate assessment of contacts can be initiated.
Healthcare and maternity guidance published in 2012 was informed by evidence that maternal clusters of GAS cases in these settings are relatively common, can develop rapidly postpartum from acquisition to symptomatic infection, and can have potentially fatal consequences. [9] [10] [11] [12] [13] Thus guidelines recommend that, following a single case of GAS in a maternity setting, investigation should be initiated, including a retrospective analysis of GAS cases in the preceding six months, thus necessitating the storage of samples, to identify linked cases and potential common exposures. 9 The aim of our study was to describe postpartum iGAS infection including management of mothers and their neonates to determine whether public health guidelines have been followed. The results inform our recommendations for the revision of current community guidance.
Methods

Data source and study period
Using HPZone TM (inFact UK Ltd, Shipley, Yorkshire, BD17 7DB UK), the case management tool used by PHE HPTs, we identified all laboratory-confirmed iGAS cases notified to local HPTs between 1 January 2010 and 31 December 2016 in mothers and/or neonates in London and the South East of England with a date of onset within 28 days of birth.
When onset was not stated in the notes, we used the earliest date of presentation to health services, date of positive specimen or date of notification.
We also identified clusters of cases in maternity services, defined as at least two cases of GAS or iGAS occurring within six months. We reviewed the records of the cases in clusters to ascertain whether there was an outbreak; defined if cases were linked by time, place or person (e.g. same midwife, same delivery room), or by emm type where this was available.
Case definitions
'iGAS' is defined as either invasive (isolation from a sterile site) or severe (where GAS has been isolated from a normally nonsterile site (e.g. the genital tract) accompanied by a severe clinical presentation, e.g. puerperal sepsis, streptococcal toxic shock syndrome (STSS) or necrotising fasciitis infection as per case definitions in the healthcare guidelines. 9 'GAS' is defined as noninvasive infections caused by GAS such as sore throats, impetigo, cellulitis or scarlet fever.
For each case of iGAS infection in a mother or neonate, we classified the counterpart as having iGAS, GAS or being well (no record of GAS or iGAS).
We also included iGAS cases in mothers with antepartum onset where delivery was precipitated by the iGAS infection.
Incidence
We calculated the incidence rates for mothers and neonates diagnosed with iGAS infection based on ONS statistics for the total number of live births and maternities (leading to live births) in London and the South East between 2010 and 2016.
14 To calculate a yearly rate for infection from a 28-day rate, we multiplied estimates by 365.25/28. OPEN-EPI Version 3 was used for calculation of confidence intervals according to the Poisson distribution.
Core outcomes were not relevant to this study.
There was no direct patient or public involvement in this study.
No funding was obtained for this study.
Results
A total of 155 cases were included in our study comprising 134 mothers and 21 neonates with iGAS infection. In two pairs, both the mother and the baby had iGAS infection, making 153 pairs in total.
Of the 134 cases of maternal iGAS infection reported in 1 598 069 live maternities, 122 (91%) had an asymptomatic newborn, 10 (7%) had a newborn who developed GAS infection and in two cases (1.5%) the newborn also had iGAS infection.
Of the 21 neonatal iGAS cases reported in 1 618 169 babies, the majority (16, 76%) had mothers who were recorded as clinically well. There were three (14%) mothers with noninvasive GAS infection and a further two (9.5%), as mentioned above, with iGAS infection.
Incidence
The incidence of postpartum iGAS infection increased from 62 per 100 000 person-years (py) (95% CI 32-107) in 2010 to 128 (95% CI 82-191) in 2013, fell in 2014 and then rose to 157 (95% CI 106-225) in 2016 ( Figure 1 ).
The mean incidence was 109 per 100 000 py at risk (95% CI 91-130); an 89-fold (95% CI 72-109) increase from the background rate of iGAS infection in other females aged 15-44 in London and South East (1.3 per 100 000 py at risk; derived from notifications in this group).
For neonates, the annual incidence in the 28-day period ranged from 0 to 29 per 100 000 py, a mean of 15 (95% CI 9-23) per 100 000 py.
Timing of onset
For the majority of maternal iGAS cases (116/134, 87%), onset occurred within 7 days of delivery ( Figure 2 ). For 40 cases (30%), the onset time was on the day of delivery and the median onset time was 2 days after delivery [interquartile range (IQR) of 0-5 days]. Three cases of iGAS occurred in mothers where the decision to deliver was precipitated by infection; thus these had a date of onset prior to delivery ranging from 1 to 3 days.
The majority of the 21 neonatal iGAS cases (12, 57%) had an onset within the first 2 weeks following delivery ( Figure 2 ). Modal onset time was day 12 for three cases (14%) and day 15 for three cases (14%). The median onset time was 12 days after delivery (IQR of 7-15 days).
In the 15 instances where both the mother and neonate were symptomatic, mothers were more likely to present first (10, 67%) ( Figure 2 ). In the three cases where the neonate presented first, two of the mothers were reported as having a sore throat and the third was asymptomatic at the time of the neonate's illness but was diagnosed with GAS by high vaginal swab (HVS) around the time of delivery prior to the neonate's presentation. In the two pairs with dual iGAS infection, both mother and child were diagnosed on the same day.
Presentation
The majority of maternal infections had a genital tract focus (82/134 cases, 61%) or were directly related to caesarean section wound site (two cases, 1%) or from the urinary tract (four cases, 3%) ( Table 1) . However, 40 (30%) had a systemic presentation, of which three presented with septic shock. Other sites included respiratory tract (three cases, 2%), necrotising fasciitis affecting a limb, or unspecified site (two cases, 1%) and mastitis (one case, 0.7%).
In 17 of 21 neonatal cases where presentation at onset was specified, seven (41%) were recorded as presenting with sepsis and five (29%) with pyrexia. The remaining cases presented with respiratory distress (two cases, 12%), infections of the umbilicus or ear (two cases, 12%) or hypoxic ischaemic encephalopathy (one case, 6%). Half of all neonatal cases had multiple presentations.
Microbiological diagnosis
Of the maternal iGAS cases where a diagnostic specimen could be determined from the records (133/134, 99%), the majority were taken from normally sterile sites (97/133, 73%), most commonly blood culture (94/97, 97%), and three cases (3%) from other sterile sites including pleura, peritoneal aspirate and tissue (Table 2) .
Thirty-six maternal iGAS cases (36/133, 27%) were diagnosed using specimens from nonsterile sites only, most commonly HVS (26/36, 72%). One-third (12/36) of these cases presented with systemic sepsis, according to the notes.
Similarly, most neonates with iGAS were diagnosed by positive blood culture (19/21, 95%). In one of the two *One mother had a clinical diagnosis based on systemic features and her newborn was symptomatic and had GAS cultured. remaining cases, GAS was isolated from a sputum sample when the baby was transferred to a paediatric intensive care unit (PICU) due to intermittent apnoea. In the other case, the diagnostic specimen was not recorded, but the baby had a severe clinical presentation (hypoxic ischaemic encephalopathy).
Mode of delivery
Mode of delivery was recorded for 85 of 134 (63%) maternal iGAS cases. The most common was vaginal delivery without instrumentation (65, 76%), with a further six (7%) mothers having an instrumental vaginal delivery with forceps or vacuum extraction. Fourteen mothers (16%) had a 
Place of treatment and severity
Of the 130 (97%) mothers for whom the place of treatment was recorded, 107 (82%) were managed in a ward, 20 (15%) required intensive care (ICU) or high dependency units (HDU) and three (2%) were managed in the community.
Treatment setting was recorded for six (29%) of the 21 neonatal cases of iGAS infection cases. Four required ICU treatment, one (17%) was managed on ward, and one (17%) was managed as an outpatient.
There were no maternal or neonatal deaths.
Evaluation of adherence to guidelines
Seventeen (13%) of the 134 maternal iGAS cases had a household contact who already had GAS-like symptoms such as sore throat prior to the mother's diagnosis, in most cases her partner and/or other children. In accordance with national guidance, treatment was advised for symptomatic household contacts in all instances.
Administration of chemoprophylaxis
For the 21 babies with iGAS, five mothers had iGAS or GAS infection (thus requiring treatment). Hence, there were 16 asymptomatic mothers, 15 of whom were advised chemoprophylaxis according to guidance. The other mother had already received prophylaxis at the time of delivery following a positive HVS test result when the baby became ill 3 weeks later.
Of the 134 women with iGAS infection, 122 (91%) had asymptomatic neonates requiring prophylaxis. Of these, the majority (110, 90%) received chemoprophylaxis (where specified, either oral or intravenous, penicillins, Azithromycin, Co-amoxiclav) with no adverse effects recorded.
Where specified, neonatal prophylaxis was mostly with penicillins, but alternatives were Azithromycin, Cefotaxime, Gentamicin (with a penicillin or alone). Of the 12 (10%) atrisk neonates who did not receive full prophylaxis, eight were born between 2010 and 2013 and four in 2014 or after. In three cases, paediatricians acted on the results of swabs taken from the neonate: one baby had antibiotics withdrawn after swabs were negative; antibiotics were not started for one baby as the swabs were negative; and for the third baby, there was no record of the final action pending the swab result. In four instances, guidance was sent, although there was no specific direction to advise antibiotics for the neonate (this was within the guidance) and one case where infection control had instructed to check the condition of the baby and siblings but there was no evidence that chemoprophylaxis was advised. In a further two cases, there was no information in the case notes, and in two cases delayed notification of the maternal iGAS infection to the HPT meant it was too late to take any action.
Maternity service clusters
We found 20 maternity service clusters where there were at least two cases of GAS or iGAS within a 6-month period (Table 2 ) with 59 associated cases (including 26 maternal iGAS cases, 28 maternal GAS cases, one neonatal iGAS case and four neonatal GAS cases).
In nine investigations (six after guidance was issued), there were no saved specimens from the earlier cases, so it was not possible microbiologically to investigate any potential link. In a further six investigations, none of the cases was linked as they had different emm types.
In five maternity clusters where cases had the same emm type, investigations included prospective case finding and screening of healthcare workers who provided care to the cases. In three instances, this was part of a mixed cluster and/or there was no link between the cases with the same emm type; also it was a common emm type, thus the cluster could be attributed to a rise in community-acquired infection. In two clusters, there was evidence of a link suggesting an outbreak. In one unit the two mothers had delivered within four days of one another in the same delivery room but the staff member who was a common link between the cases tested negative for GAS. The room was deep cleaned and active case finding of 29 other women who had delivered in that room showed that none had a positive GAS result. In the other cluster, there were two women who had been attended by the same staff members, in the same delivery suite, and had transferred to the same postnatal ward. However, the second case, who was admitted 24 hours after the first, had a symptomatic family contact, and the infection was thus considered community-acquired. Actions were deep cleaning, staff swabbing and prospective surveillance.
Discussion
Main findings
Incidence and onset of GAS Notably onset of GAS occurred rapidly in mothers, within 7 days of delivery in the majority of cases (87%), with 30% of women showing signs of infection on the day of delivery compared with modal values of 12 and 15 days for neonates. Early onset GAS has been described in other studies. 15 In cases of dual infection, mothers were generally diagnosed with iGAS before their newborns, and in cases where neonates were diagnosed first; mothers appeared to show signs of infection around the same time. In addition, the distribution of onset was smaller for mothers (IQR 0-5 days) than for neonates (IQR 7-15 days), indicating a narrower time window between acquisition and onset.
From 2010 to 2013, iGAS cases in postpartum women increased; likely due to improved reporting, as iGAS infection became a notifiable disease in 2010 and the hospital guidance was issued in 2011, which defined iGAS as including disease from nonsterile sites. 16 The subsequent rise in incidence to 2016 should be interpreted with caution as the absolute number of cases is small (22 in 2013 to 27 in 2016) and the confidence intervals imply no statistically significant increase. However, the overall incidence of iGAS in England has increased in this period from 2.47 (2011) to 4.53 (2016) per 100 000 py. 17, 18 The incidence of severe postpartum GAS infection described is higher than in US studies (59 per 100 000 person-years) because of our inclusion of severe GAS cases. However, if the definition were restricted to invasive GAS diagnosed from blood cultures or necrotising fasciitis, this would approximate to a similar rate of 77 per 100 000 py. 15, 19 There were no deaths in the current study consistent with the observed lower mortality of iGAS in the prepartum period compared with other settings, although differences in strain virulence and co-morbidity may explain this.
Diagnosis and management of maternal iGAS
The majority of maternal infections had a genital tract focus, and this is commonly the underlying cause for systemic presentation. However, iGAS infection in postpartum women does not always arise from the genital tract, and infection may be acquired through the respiratory route and is usually from external sources. 2, 20 This highlights the importance of frontline services in recognising the array of possible presentations of GAS infection in postpartum women. We found that 26% of maternal iGAS cases were diagnosed using samples obtained from nonsterile sites; these cases were treated as iGAS due to systemic or severe clinical presentation. This highlights the fact that severe puerperal sepsis, requiring prophylaxis of the neonate and follow up in line with public health guidance, relies on the judgement of a clinician, and that a high level of suspicion is always warranted, as no single risk factor, clinical sign or laboratory index can indicate this serious complication. 21 
Strengths and limitations
The main strength of our study was that all cases of maternal and neonatal GAS infection notified to HPTs within the first 28 days following parturition were available to review. As iGAS infection became notifiable in 2010, we expect all incident cases to be in our study and the level of under-reporting to be small.
The main limitation was that our study was only based on data collected for public health purposes and therefore lacks the level of detail of medical notes. Some areas of interest such as mode of delivery, clinical sequelae and morbidity data on neonates are not required for public health management, so were not routinely documented. Gaps in areas of key information such as method of diagnosis were still apparent, although in recent years the quality of data recording has improved. Furthermore, our study cannot directly assess whether the guidelines are effective in reducing iGAS infections in this group. We have no comparator data as this is a descriptive study. In both incidents where mother and baby were affected, there was simultaneous presentation, so prophylaxis could not have been prescribed. However, there were no other dual iGAS infections, suggesting that, in other potential cases, dual cases of iGAS may have been averted by prophylaxis. In a national study of household transmission, to prevent a case of iGAS, only 50 mothers and neonates have to be given prophylaxis, and mothers/ babies accounted for one in five of dual cases. 5 However, there is no study assessing the effectiveness of the guidelines in practice, although this is much needed.
As the guidance advising prophylaxis is limited to the first 28 days postpartum, we did not describe the late onset iGAS cases in the puerperium, although these should still be notifiable.
In the earlier years of our study in particular, cases were sometimes not defined as iGAS based purely on a negative blood culture. However, in our study the revision of the notes has allowed us to apply the definitions according to current guidance. Therefore, the misclassification of cases is likely to have been improved.
Interpretation and recommendations
Despite the majority of cases being managed correctly according to UK guidelines, there is still progress to be made in reducing the risk of iGAS infection and sepsis in neonates born to mothers with iGAS infection by ensuring they all receive appropriate prophylaxis.
Although the reasons for failure to administer chemoprophylaxis to at-risk neonates varied, we found that for three of the 12 cases where delay occurred, it was because the paediatrician preferred to wait for the outcome of swab results before making a decision on antibiotic prophylaxis. However, as our results suggest that neonatal GAS infection is generally acquired later than in mothers, swabs taken at birth are unlikely to yield any positive results. A similar review suggests that ambiguity surrounding responsibility for neonates' prophylaxis contributed to a shortfall in the number of neonates receiving prophylaxis. 22 Furthermore, paediatricians may be reluctant to prescribe medication to a well neonate if they perceive the potential harms to be greater than the benefits. With a high risk of neonatal infection and the fact that delaying prophylaxis could be potentially deleterious, clinical teams should respond quickly to suspicion of GAS infection in postpartum women and neonates.
We only found a small proportion of household contacts to be symptomatic; given the usual acquisition of GAS from a symptomatic contact, infection may have been acquired from other contacts. However, treatment of symptomatic household contacts should also be prioritised to minimise the risk of spread of infection in household settings.
Finally, to improve maternity service investigations, consider whether the care pathway (both in-patient and domiciliary) has been checked, as outbreaks involving district nursing teams have been described. 23 Maternity isolates must be saved for at least 6 months given potential prolonged gaps to facilitate any future investigation of potentially linked cases.
Conclusion
In the context of rising iGAS incidence, prophylaxis for mothers and their neonates must be encouraged. Early diagnosis and notification allows the risk to the neonate and family to be minimised. Improvements could be made in strengthening hospital clinical protocols and the communication of risk and national guidance to clinical teams managing community-associated cases. 
